Hansen Pharmaceutical: The net profit for the third quarter was 13.9868 million yuan, a year-on-year decrease of 53.78%

Hansen Pharmaceutical announced that its revenue for the third quarter was 232 million yuan, an increase of 8.62% year-on-year; net profit was 13.9868 million yuan, a decrease of 53.78% year-on-year. Revenue for the first three quarters was 741 million yuan, an increase of 6.75% year-on-year; net profit was 82.5252 million yuan, a decrease of 36.88% year-on-year

Hansen Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 68.5384 million yuan, a decrease of 31.80%

Hansen Pharmaceutical released its semi-annual report for 2025, with operating revenue of 509 million yuan, a year-on-year increase of 5.91%. The net profit attributable to the parent company was 68.5384 million yuan, a year-on-year decrease of 31.80%; the net profit excluding non-recurring gains and losses was 64.7695 million yuan, a year-on-year decrease of 31.72%. The basic earnings per share were 0.1362 yuan

The A-share traditional Chinese medicine sector rapidly surged, with Xintian Pharma hitting the limit up, and YIBAI PHARMACEUTICAL, Zhendong Pharmacy, ZHONGSHENGYAOYE, Hansen Pharmaceutical, and ENWEI PHARMACEUTICAL following suit

Hansen Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 11.2572 million yuan, a year-on-year decrease of 80.68%

According to the Zhitong Finance APP, Hansen Pharmaceutical released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 269 million yuan, a year-on-year increase of 6.00%. The net profit attributable to shareholders of the listed company was 11.2572 million yuan, a year-on-year decrease of 80.68%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 9.1164 million yuan, a year-on-year decrease of 83.49%

Hansen Pharmaceutical: Net profit of 220 million yuan in 2024, a year-on-year increase of 7.43%

Hansen Pharmaceutical announced that the operating revenue for 2024 is expected to be 1.004 billion yuan, a year-on-year increase of 5.12%. The net profit attributable to shareholders of the listed company is 220 million yuan, a year-on-year increase of 7.43%. The basic earnings per share is 0.4377 yuan/share, a year-on-year increase of 7.44%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital by converting reserves into share capital